Otelixizumab |
カタログ番号GC72342 |
Otelixizumab (ChAglyCD3) is an anti-human CD3 monoclonal antibody and can be used for the research of type 1 diabetes.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 881191-44-2
Sample solution is provided at 25 µL, 10mM.
Otelixizumab (ChAglyCD3) has a dose-dependent accumulation and a half-life of about 1.5 days[2].
Otelixizumab targets the ε-chain of the CD3 T-lymphocyte surface receptor, which facilitates the activation of the autoreactive T-lymphocytes responsible for beta cell destruction[2].
Otelixizumab (ChAglyCD3) (100 μg/mouse; i.v.; once) results in durable disease remission dependent on transferable T cell–mediated tolerance in diabetic transgenic mice[1].
References:
[1]. Kuhn C, et al. Human CD3 transgenic mice: preclinical testing of antibodies promoting immune tolerance. Sci Transl Med. 2011 Feb 2;3(68):68ra10.
[2]. Guglielmi C, et al. Efficacy and safety of otelixizumab use in new-onset type 1 diabetes mellitus. Expert Opin Biol Ther. 2016 Jun;16(6):841-6.
Average Rating: 5
(Based on Reviews and 30 reference(s) in Google Scholar.)GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *